Feasibility of ECG-Based Glucose Monitoring System

Inclusion Criteria:

• Males and females, age 18 years or older.

• Subjects can communicate clearly, fully understand the informed consent form, andare aware of the rights and obligations of the study.

• Category 1: Subjects without a medical history of hyperglycemia / hypoglycemia ortype 1 / type 2 diabetes.

Category 2: Subjects having diabetes mellitus (DM) and HbA1c value of. 5.5% to 10%, with eGFR ≥ 60 mL/min.

Category 3: Subjects having chronic kidney disease (CKD) and diabetes. mellitus (DM), with eGFR < 60 mL/min.

• Willing and able to participate in all aspects of the study.

Exclusion Criteria:

• Subjects suffering from insomnia or severe digestive system disorders within 3months prior to the screening visit.

• Subjects who are addicted to alcohol or caffeine.

• Existing severe cardiac conditions such as recent myocardial infarction or advancedheart failure within 6 months prior to the screening visit.

• Has experienced an episode of confirmed or suspected diabetic ketoacidosis (DKA)within 6 months prior to the screening visit.

• Subjects who are vulnerable groups or with higher risks, such as HIV carriers,pregnant women or planning to become pregnant within the study duration,breast-feeding mothers, subjects with rare diseases, physical disabilities,incurable fatal diseases, dependents in nursing homes, incapacity, or intellectualor mental disabilities.

• Has a concomitant disease or condition that may compromise subject safety such asunstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, orany other uncontrolled medical conditions.

• Any active infection or malignancy requiring acute therapy.

• Having coagulation disorders.

• Has known allergy to medical adhesives.

• Subjects using any cardiac related implantable medical devices such as a pacemakerand so on.

• Subjects on certain drugs known to cause arrhythmias or significantly impact kidneyfunction or blood glucose levels (except for the current daily use medication).

• Subjects have used defibrillators within 3 months prior to the screening visit.

• Currently participating in another device or drug study.

• Currently receiving dialysis treatment or planning to receive dialysis during thestudy.

• Any other clinical condition that, in the investigator's judgment, would potentiallycompromise study compliance or the ability to evaluate safety/efficacy.